EUCTR2006-001132-45-IT进行中（未招募）不适用
A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE AND MULTIPLE DOSE STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSE LEVELS OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED 1 THROUGH 11 MONTHS WITH PRESUMED GERD - ND
Wyeth Pharmaceuticals Inc., Wyeth Research Div., Clinical research and Development0 个研究点目标入组 56 人开始时间: 2007年3月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1 Male or female term or post term infants beyond the neonatal period 44 weeks but 12 months of age, or preterm infants with a corrected age of at least 44 weeks but 12 months at the time the informed consent is signed. 2 Have a presumptive diagnosis of GERD. The method used for the diagnosis of presumptive GERD will be recorded. 3 Weight must be 2.5 kg and 15 kg. 4 The patients may be hospitalized patients or outpatients at the time of study entry. 5 Patients must be able to swallow the suspension.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1 History of any of the following gastrointestinal disorders a Unrepaired tracheal esophageal fistula; b Gastrointestinal malabsorption. 2 Clinically significant medical or surgical abnormalities during the prestudy screening period physical examination, electrocardiogram ECG , or laboratory test, as assessed by the investigator. This includes a Unstable cardiovascular, renal, hepatic, hematologic, or endocrine disease except with prior approval of Wyeth medical monitor. b Active childhood infectious diseases eg, measles, mumps, or chickenpox .c Known coagulation disorders eg, hemophilia . 3 Known history of human immunodeficiency virus HIV or clinical manifestations of acquired immune deficiency syndrome AIDS or other immunodeficiency disorder. 4 Presence of terminal malignancy or any malignancy requiring treatment with radiation or chemotherapy within the past 6 months or if such treatment is planned within 30 days after the start of test article.5 Clinically significant laboratory abnormality of the following laboratory tests a Aspartate aminotransferase AST or alanine aminotransferase ALT 2 times upper limit of normal ULN .b Total bilirubin 2mg/dL.c Alkaline phosphatase 2 times ULN age corrected . 6 Known positive serologic test results for hepatitis B virus antigen HBsAg or hepatitis C virus HCV antibody or RNA . 7 Known hypersensitivity to proton pump inhibitors PPIs , including pantoprazole. 8 PK Portion History of treatment with PPIs within 24 hours before test article administration. PD or PK/PD Portion Patients undergoing PD assessments collection may not have had PPIs for 7 days before first test article administration. 9 PK Portion Use of histamine 2 receptor blockers H2RAs ,within 24 hours before test article administration PD or PK/PD Note Patients undergoing PD assessments may not have had H2RAs for 3 days before first test article administration. 10 Antacids are prohibited 2 hours before and after test article and 2 hours prior or during pH-metry. 11 Sucralfate, bismuth preparations, misoprostil or prokinetic agents should be discontinued 24 hours before test article administration. 12 Any disorder requiring chronic every day use of warfarin, carbamazepine, or phenytoin. 13 Participation in any other investigational drug trial or experimental trial within 30 days before administration of test article without approval from the Wyeth medical monitor. 14 History of recent acute-life threatening events due to manifestations of GERD. 15 Patient or PARENT felt to be unable to comply with study procedures in the investigator s opinion. 16 Continuous enteral feeding or any feeding more frequently than every 3 hours is prohibited in patients participating in PD or PK/PD portion of the study. 17 Use of special diets or herbal or alternative medication that might affect the metabolism of test article without prior approval of the Wyeth medical monitor.
研究者
相似试验
进行中（未招募）
不适用
A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE AND MULTIPLE DOSE STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSE LEVELS OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED 1 THROUGH 11 MONTHS WITH PRESUMED GERD.INFANTS AGED 1 THROUGH 11 MONTHS WITH PRESUMED GERDEUCTR2006-001132-45-DEWyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development56
进行中（未招募）
不适用
A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE AND MULTIPLE DOSE STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSE LEVELS OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED 1 THROUGH 11 MONTHS WITH PRESUMED GERD.EUCTR2006-001132-45-BEWyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development56
进行中（未招募）
1 期
A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE AND MULTIPLE DOSE STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSE LEVELS OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED 1 THROUGH 11 MONTHS WITH PRESUMED GERD.INFANTS AGED 1 THROUGH 11 MONTHS WITH PRESUMED GERDEUCTR2006-001132-45-FRWyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development56
进行中（未招募）
1 期
A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic RO5534262 versus No Prophylaxis in Hemophilia A Patients with InhibitorsHemophilia A with InhibitorsMedDRA version: 18.0 Level: LLT Classification code 10060612 Term: Hemophilia A System Organ Class: 100000004850MedDRA version: 18.0 Level: LLT Classification code 10053751 Term: Hemophilia A with anti factor VIII System Organ Class: 100000004850EUCTR2015-002866-21-ESRoche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.109
进行中（未招募）
1 期
oEUCTR2019-000990-22-NLGARDP FOUNDATIO1,092